Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Alpelisib × 1 year × Clear all

Phase

Phase 2 15 Phase 3 7 Phase 1/2 5 Phase 1 2 Phase NA 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Endocrine Neoplasia Type 1 1

Interventions

Dexamethasone 12 Saline Solution 8 Fluorouracil 8 Carboplatin 8 Bupivacaine 8 pembrolizumab 6 anlotinib 6 Tobacco Use Cessation Devices 6 Specimen Handling 6 Prednisone 6 Nivolumab 6 Magnetic Resonance Spectroscopy 6 Lenalidomide 6 Human Papillomavirus Recombinant Vaccine nonavalent 6 Cisplatin 6 Bevacizumab 6 Standard of Care 5 Rituximab 5 Propofol 5 Bortezomib 5 trametinib 4 lenvatinib 4 enzalutamide 4 dabrafenib 4 cabozantinib 4 Sodium Chloride 4 Ropivacaine 4 Paclitaxel 4 Letrozole 4 Imatinib Mesylate 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05631795 2025-12-03

ALPINIST

Novartis

Phase 4 Completed

Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡